Feature | ACC | March 22, 2017

ACC 2017 Late-Breaking Trials

Latest clinical data in cardiology will be presented at the 2017 American College of Cardiology meeting

ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies

Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presented at ACC.17 March 17-19, in Washington, D.C. The studies are linked to articles specific to the trial presentations.

ACC.17 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials
Friday, March 17

FOURIER: Primary Results of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial

SPIRE 1 and SPIRE 2: Safety and Cardiovascular Event Efficacy of Bococizumab Among 27,000 High-risk Patients

SURTAVI: Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis Compared With Surgical Aortic Valve Replacement in Patients at Intermediate Surgical Risk: First Results From the SURTAVI Clinical Trial

 

Featured Clinical Research I
Friday, March 17

RESET-HCM: Testing Safety and Efficacy: The Randomized Exploratory Study of Exercise Training in Hypertrophic Cardiomyopathy

S2P Study: Results of MRI-Based Screening Study of 5130 Candidates for Sports Participation

MR-INFORM: Stress Perfusion Imaging to Guide the Management of Patients With Stable Coronary Artery Disease

Effects of Different Front-of-Pack Food Labelling Formats on the Healthiness of Food Purchases — a Randomized Trial

Native South American Tsimane Have the Lowest Levels of Coronary Atherosclerosis Ever Reported

ORION 1: LDL-C Reduction From 6 to 9 Months Following Single or Second Injection of Inclisiran a Novel siRNA Compound: Primary Efficacy and Safety Outcomes of the ORION 1 Trial
 

Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Saturday, March 18

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

GEMINI-ACS-1: A Randomized Trial Evaluating Clinically Significant Bleeding With Low-Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, for Patients After Acute Coronary Syndromes

REACH: e-Counseling for Self-Care Adherence Adds Therapeutic Benefit for Hypertension: The REACH Trial

CARAT: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis: Results of the CARAT Study

EBBINGHAUS: Primary Results of EBBINGHAUS, a Cognitive Study of Patients Enrolled in the FOURIER Trial

 

Late-Breaking Clinical Trials
Saturday, March 18

COMPARE-ACUTE: FFR Guided Acute Complete Revascularization Versus Culprit Lesion Only Treatment in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Multi Vessel Disease

DEFINE-FLAIR: Primary Results of DEFINE-FLAIR: A Multi-Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization

IFR-SWEDEHEART: Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve Guided Intervention (IFR-SWEDEHEART): A Multicenter, Prospective, Registry-Based Randomized Clinical Trial

DECISION CTO: Drug-Eluting Stent Versus Optimal Medical Therapy in Patients With Coronary Chronic Total Occlusion: DECISION CTO Randomized Trial

ABSORB III: Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Disease: Two-Year Outcomes From the ABSORB III Trial
 

 

Featured Interventional Clinical Research II
Saturday, March 18

ADVICE Study: Real-World Comparative Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in the United States: An Analysis From Two U.S. Registries Linked to Medicare Data

STS/ACC TVT Registry: Comparison of In-Hospital and 1-Year Outcomes of Transcatheter Aortic Valve Replacement for Failed Surgical Bioprosthesis Versus Native Aortic Stenosis From the STS/ACC TVT Registry

Procedural and Clinical Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis

RAD Matrix: Radiation Exposure and Vascular Access in Acute Coronary Syndromes: The RAD Matrix Study

Clinical Outcomes at 1-Year After Commercial Transcatheter Mitral Valve Repair in the United States

 

Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Sunday, March 19

• LEVO-CTS: Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Primary Results of the LEVO-CTS Trial

Cerebral Embolic Protection Devices During Surgical Aortic Valve Replacement: A Randomized Trial From the Cardiothoracic Surgical Trials Network

Silent Cerebral Microbleeds During TAVR: Insight From a Prospective Cerebral MRI Cohort

RESOLVE and SAVORY: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Aortic Valves: Results From RESOLVE and SAVORY Registries

VISION Study: Relationship Between High Sensitive Troponin T Measurements and 30-Day Mortality After Noncardiac Surgery

• SPIRE-1 and SPIRE-2 - PCSK9 inhibitor bococizumab given on top of effective statin therapy

 

Late-Breaking Clinical Trials
Sunday, March 19

RE-CIRCUIT: Safety and Efficacy of Uninterrupted Anticoagulation With Dabigatran Etexilate Versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study

ARISTOTLE: Digoxin and Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

Comparative Effectiveness of Left Atrial Appendage Occlusion Among Atrial Fibrillation Patients Undergoing Cardiac Surgery: A Report From the Society of Thoracic Surgeons Adult Cardiac Surgery Database

GIFT of Warfarin: Benefit of Pharmacogenetic Dosing

SPAIN Study: Randomized Placebo Controlled Trial of Closed Loop Stimulation in Recurrent Reflex Vasovagal Syncope

 

Featured Clinical Research III
Sunday, March 19

Early Challenges for PSCK9 Inhibitor Prescriptions and Patients: Rejections and Rates Unfilled

STOMP: The Effect of High-Dose Atorvastatin on Neuronal Activity and Cognitive Function

• Outcomes for 15,259 U.S. Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella

CVD-REAL Study: Lower Rates of Hospitalization for Heart Failure in New Users of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs — Real-World Data From Four Countries and More Than 360,000 Patients: The CVD-REAL Study

Paroxysmal Atrial Fibrillation Is Associated With Worse Clinical Outcomes Than Persistent/Permanent Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction

Reduction in Heart Failure Hospitalizations With Ambulatory Hemodynamic Monitoring Seen in Clinical Trials Is Maintained in the Real World

 

See the late-breaking trials from ACC.16 with links to stories.

TCT 2016 Late-breaking Trials and First Reports
 

For more information: accscientificsession.acc.org/Plan-Your-Program/Late-Breakers


Related Content

News | ACC

July 31, 2024 — The American College of Cardiology (ACC) has announced its release of the ACC Remote Patient Management ...

Home July 31, 2024
Home
News | ACC

July 10, 2024 — Findings from an observational analysis of ARISE-HF trial participants, newly-published in the Journal ...

Home July 10, 2024
Home
News | ACC

May 9, 2024 — The American College of Cardiology (ACC) and the American Heart Association (AHA) today released a new ...

Home May 09, 2024
Home
News | ACC

April 11, 2024 — One-year success rates from angioplasty procedures to open clogged arteries in the legs were ...

Home April 11, 2024
Home
News | ACC

April 6, 2024 — The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST ...

Home April 06, 2024
Home
Feature | ACC | Christine Book

April 3, 2024 — In gearing up for its Annual Scientific Session, ACC.24, amidst the 75th anniversary of the organization ...

Home April 03, 2024
Home
News | ACC

March 26, 2024 — Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II ...

Home March 26, 2024
Home
Feature | ACC | By Melinda Taschetta-Millane

The American College of Cardiology (ACC) has announced key educational and programming highlights for its ACC 73rd ...

Home March 25, 2024
Home
News | ACC

March 21, 2024 — Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the goal ...

Home March 21, 2024
Home
News | ACC

March 7, 2024 — The American College of Cardiology (ACC) has announced its line-up of keynote speakers for the ACC 73rd ...

Home March 07, 2024
Home
Subscribe Now